While many classes of chemotherapeutic agents exist to treat solid tumors, few can generate
a lasting response without substantial off-target toxicity despite significant scientific …

The field of clinical nanomaterials is enlarging steadily, with more than a billion US dollars of
funding allocated to research by US government agencies in the past decade. The first …

Simple Summary According to the International Agency for Research on Cancer (IARC), in
2018, the global burden of cancer is expected to grow to 27.5 million new cancer cases by …

Given extensive reports of anticancer nanomedicines in preclinical studies, why is there
such a paucity of clinical trials using these therapies? Nanotechnology can certainly deliver …

Anticancer nanomedicines have been studied over 30 years, but fewer than 10 formulations
have been approved for clinical therapy today. Despite abundant options of anticancer …

An increasing amount of evidence has demonstrated the diverse functionalities of
nanomaterials in oncotherapies such as drug delivery, imaging, and killing cancer cells. This …

The justification of cancer nanomedicine relies on enhanced permeation (EP) and retention
(R) effect and the capability of intracellular targeting due primarily to size after internalization …

Nanomedicines are extensively explored for cancer therapy. By delivering drug molecules
more efficiently to pathological sites and by attenuating their accumulation in healthy organs …

The high global incidence of cancer is associated with high rates of mortality and morbidity
worldwide. By taking advantage of the properties of matter at the nanoscale, nanomedicine …

The majority of nanomedicines in (pre) clinical trials are based on established drugs, such
as doxorubicin and paclitaxel. Does that make sense? To some extent yes, because a lot of …